Back to search

Article

Targeting MDM2 homodimer and heterodimer disruption with DRx-098D in TP53 wild-type and mutant cancer cells

2025-01-14

Abstract excerpt

Novel pharmacological strategies capable of inhibiting pro-oncogenic MDM2 beyond its p53-dependent functions represents an increasingly attractive therapeutic strategy to treating solid and haematological cancers that are depdendent upon MDM2/MDMX, regardless of TP53 mutational status. Utilising a novel first-in-class cell-penetrating peptide disruptor of MDM2 homo- and heterodimerisation (DRx-098D), we demonstrat...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ce416f44-3022-5a8a-81bb-3337362d52fc
DOI
10.1101/2025.01.10.632324
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Targeting MDM2 homodimer and heterodimer disruption with DRx-098D in TP53 wild-type and mutant cancer cellsDOI 10.1101/2025.01.10.632324
Targeting the p53–MDM2 interaction to treat cancerSemantic proximity
A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018)Semantic proximity
Clinical Overview of MDM2/X-Targeted TherapiesSemantic proximity
Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011 – present)Semantic proximity
Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) AntagonistsSemantic proximity
Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia.Semantic proximity
MDM2: current research status and prospects of tumor treatmentSemantic proximity
Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trialsSemantic proximity
MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancerSemantic proximity
Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?Semantic proximity
Molecular Pathways: Targeting Mdm2 and Mdm4 in Cancer TherapySemantic proximity
The p53/MDM2/MDMX-targeted therapies—a clinical synopsisSemantic proximity
Select a neighboring publication to make it the new centre.